Relative Intelligence · Life Sciences Tools

How Danaher (DHR) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on DHR alone. It places DHR (Danaher Corporation) against 19 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where DHR stands in the market, and of the alternatives worth a closer look.
Period covered: DHR's full trading record, from October 1986 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowThe slide is DHR's own: it is 22.0% below its high, against 1.3% for the S&P 500. On the flip side, over the past 3 months, DHR rose 11.6% against 3.9% for the S&P 500 and 3.2% for the Nasdaq 100. At a glance ↓
- Stock or market?DHR's 11.6% gain over the past 3 months is part of a broader life sciences tools rally: the life sciences tools ETF IHI (iShares U.S. Medical Devices ETF) rose 7.5%, with TMO (Thermo Fisher Scientific, up 30.7%) and A (Agilent Technologies, up 33.1%). Its life sciences tool peers did not move as one over the past 3 months: A rose 33.1%, while BRKR (Bruker) fell 0.3%.
- Past 1 to 3 yearsA ahead of 65% of stocks worth at least $300 million over 10 years, but behind 71% of the stocks worth at least $300 million over 3 years. DHR has trailed the market, rising 8.3% over the past year against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (10.8% against 89.3%). Market rank ↓
- Long termDHR turned $10,000 into $33,200 over the past decade, against $42,100 in the S&P 500. On the flip side, year by year, DHR has outpaced the S&P 500 69% of the time since 1997. Growth of $10,000 ↓
- In a crashIn the 2022 bear market, DHR held up better than A (Agilent Technologies), WAT and ILMN; only TMO (Thermo Fisher Scientific) and QGEN fell less. DHR fell less than the S&P 500 in three of the last four sell-offs, including the Covid crash (25.9% against 33.7%). Crash tests ↓
- DiversificationDHR is some diversification, but not a hedge: a correlation of 0.54 with the S&P 500 over 5 years and 0.55 with the total US market, more closely than 81% of stocks worth at least $300 million. When the S&P 500 had a down month, DHR usually fell with it (18 of 22 months). By year ↓
- Better options
- Popular alternatives
- DGX (Quest Diagnostics), LH (Labcorp) and QGEN (Qiagen) earned more than DHR with less volatility over the past 5 years. DGX returned 12.3% a year at 22.5% volatility, against a loss of 3.8% a year at 29.1%.
- Nearby categories and themes
- GILD (Gilead Sciences, biotechnology) and AMGN (Amgen, biotechnology) earned more than DHR with less volatility over the past 5 years. GILD returned 22.8% a year at 24.9% volatility, against a loss of 3.8% a year at 29.1%.
- Whole market
- 1,360 of the 3,633 stocks and funds worth at least $500 million earned more than DHR with less volatility over the past 5 years, among them VTI (Vanguard Morningstar Total Stock Market ETF), VOO (Vanguard S&P 500 ETF) and BRK-B (Berkshire Hathaway).
How much would $10,000 in DHR have grown?
This chart tracks a hypothetical $10,000 investment in DHR over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of DHR over the same span and DHR's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
- $10,000 invested in DHR at the end of September 1997 would have grown to $777,394 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Six of the eight other investments on the chart ended ahead of DHR, and MNST finished highest, at $45,663,831.
Choose a period
From the end of September 1997 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 51 of the 1,042 stocks and funds worth at least $500 million that traded the whole period ended ahead of DHR; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- MNST$46M+456,538% total · +33.7% a year
- AAPL$21M+205,249% total · +30.1% a year
- AMZN$11M+114,749% total · +27.5% a year
- RGEN$2M+16,470% total · +19.3% a year
- GILD$2M+15,614% total · +19.1% a year
- DGX$784,474+7,745% total · +16.2% a year
- DHR$777,394+7,674% total · +16.2% a year
- TMO$235,386+2,254% total · +11.5% a year
- RVTY$198,041+1,880% total · +10.8% a year
- SPY (S&P 500)$132,907+1,229% total · +9.3% a year
From the end of September 2021 to the end of September 2026. Hover over a fund in the key to pick out its line. 2,847 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of DHR; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- DGX$17,761+77.6% total · +12.2% a year
- LH$13,440+34.4% total · +6.1% a year
- TMO$11,986+19.9% total · +3.7% a year
- A$11,334+13.3% total · +2.5% a year
- IQV$11,224+12.2% total · +2.3% a year
- MTD$10,970+9.7% total · +1.9% a year
- QGEN$9,482−5.2% total · −1.1% a year
- RVTY$8,929−10.7% total · −2.2% a year
- DHR$8,422−15.8% total · −3.4% a year
DHR at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
- DHR is still 22.0% below its all-time high.
- DHR's deepest decline since it began trading in 1986 was 60.9%, from September to December 1987. It took six months from the low to climb back to its old high.
- Over 29 full calendar years, DHR's best was 2016, when it returned 73.2%, and its worst was 2008, when it lost 35.4%. It lost money in eight of those years.
The company
- Market value
- $157B
- Industry
- Medical - Diagnostics & Research
- Price history from
- October 1986
Returns
- Past 1 year
- +8.3%total return
- Past 3 years
- +10.8%+3.5% a year
- Past 5 years
- −17.6%−3.8% a year
- Past 10 years
- +232%+12.7% a year
- Best calendar year
- +73.2%2016
- Worst calendar year
- −35.4%2008
- Losing years
- 8 of 29full calendar years
Risk
- Volatility
- 29.1%typical yearly swing, 5 years
- Sharpe ratio
- 0.01return per unit of risk, 5 years
- Worst decline ever
- −60.9%Sep 1987 to Dec 1987
- From its all-time high
- −22.0%below the peak
DHR against the whole market
Where DHR ranks among every stock and fund, and what across the market has done better.
How does DHR rank among all stocks?
This section ranks DHR on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how DHR stacks up against its peers, these rankings show where it stands in the market as a whole.
- DHR's worst decline of the past 10 years ranks in the top 12% of the 2,187 stocks worth at least $300 million, where the top fell the least.
- On return for the risk taken (the Sharpe ratio), DHR ranks in the bottom 20% of the 2,893 stocks worth at least $300 million.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | DHR | Rank | Standing |
|---|---|---|---|
| 1-year return | +8.3% | 1,653 of 3,287 | top 50% |
| 3-year return | +10.8% | 2,146 of 3,017 | bottom 30% |
| 5-year return | −17.6% | 1,972 of 2,893 | bottom 33% |
| 10-year return | +232% | 767 of 2,202 | top 35% |
| Volatility, 5 years | 29.1% | 648 of 2,893 | top 22% |
| Sharpe ratio, 5 years | 0.01 | 2,317 of 2,893 | bottom 21% |
| Worst decline, past 10 years | −43.8% | 253 of 2,187 | top 12% |
What has beaten DHR on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). DHR sits where the dashed lines cross. Anything in the green box above and to the left earned more than DHR with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 442 stocks and 918 ETFs worth at least $500 million sit in the green region: each earned more than DHR over the past 5 years with smaller price swings. That is 37% of the 3,633 screened.
- Among those with at least half DHR's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 15% less than DHR's 29.1%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 0.01 for DHR.
- Among DHR's popular alternatives, DGX, LH and QGEN are in the region. DGX earned 12.3% a year against a loss of 3.8% a year for DHR, at 22.5% volatility, 23% less than DHR's 29.1%.
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to DHR; faint dots are 88 more of the 1,360 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- Popular alternatives
- Same and neighboring categories, and shared themes
- The whole market
- Others in the green region
Is there a better investment than DHR?
Investments that beat DHR over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Among DHR's popular alternatives, DGX, LH and QGEN earned more than DHR with less volatility over the past 5 years. DGX returned 12.3% a year at 22.5% volatility, against a loss of 3.8% a year at 29.1%.
- Looking beyond its popular alternatives, GILD (biotechnology) and AMGN (biotechnology) earned more than DHR with less volatility over the past 5 years. GILD returned 22.8% a year at 24.9% volatility, against a loss of 3.8% a year at 29.1%.
- Across the whole market, 1,360 of the 3,633 stocks and funds worth at least $500 million earned more than DHR with less volatility over the past 5 years, among them VTI, VOO and BRK-B.
How this works
The table below lists investments that beat DHR over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks DHR's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than DHR follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than DHR's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× DHR's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than DHR's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with DHR?lower diversifies more | Expenseper year | |||
| −3.8% | 29.1% | 0.01 | −43.8% | +232% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.54 | 0.09% | |||
| Popular alternativesbest 6 shownThe investments people most often weigh against DHR. 11 of 19 passed at least one test. | |||||||||
DGXQuest Diagnostics Incorporated · Medical Diagnostics | Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.3% | 22.5% | 0.63 | −36.6% | +243% | 0.26 | — | |
LHLabcorp Holdings Inc. · Medical Diagnostics | Higher return, lower volatilityHigher return in most periods | +7.3% | 23.8% | 0.42 | −46.6% | +184% | 0.43 | — | |
QGENQiagen N.V. · Life Sciences Tools | Higher return, lower volatilityHigher return in most periods | +0.6% | 26.9% | 0.15 | −41.4% | +111% | 0.59 | — | |
| Higher return, similar volatilityHigher return in most periods | +2.9% | 27.8% | 0.24 | −40.9% | +366% | 0.76 | — | ||
| Higher return, similar volatilityHigher return in most periods | +2.6% | 30.6% | 0.24 | −43.2% | +306% | 0.68 | — | ||
| Higher return, lower volatility | −1.7% | 23.1% | 0.04 | −39.6% | +204% | 0.35 | — | ||
| Same and neighboring categories, and shared themesbest 6 shownEverything else in Life Sciences Tools and the categories next to it (Biotechnology, Medical Diagnostics, Contract Research, Pharmaceuticals), plus DHR's specific themes. 27 of 86 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.08 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.35 | — | ||
| Higher return, lower volatilityHigher return in most periods | +26.1% | 23.4% | 1.11 | −45.1% | +603% | 0.26 | — | ||
| Higher return, lower volatilityHigher return in most periods | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.18 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +12.7% | 17.9% | 0.76 | −27.4% | +196% | 0.28 | — | ||
| Higher return, similar volatilityHigher return in most periods | +22.6% | 29.1% | 0.85 | −41.6% | +521% | 0.14 | — | ||
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 1,829 of 3,528 passed at least one test. | |||||||||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.23 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.20 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.08 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +18.4% | 26.0% | 0.78 | −35.1% | +779% | 0.45 | 0.09% | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +17.2% | 24.9% | 0.77 | −30.4% | +285% | 0.25 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +8.4% | 15.3% | 0.60 | −28.4% | +202% | 0.61 | 0.08% | ||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periods | +18.5% | 28.0% | 0.75 | −38.5% | +1,168% | 0.43 | — | ||
| Similar return, lower volatility | −4.3% | 14.1% | -0.24 | −30.4% | — | 0.49 | — | ||
What these numbers mean for DHR
- Annual return
- DHR lost 3.8% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $8,240. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- DHR's volatility over the past 5 years was 29.1%, 1.7 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, DHR's return lands within 29.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- DHR's Sharpe ratio over the past 5 years was 0.01, against 0.79 for the S&P 500, so DHR earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- DHR's worst fall from a peak to a low over the past 10 years was 43.8%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 43.8% fall takes a 78.0% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, DHR's monthly returns had a correlation of 0.54 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against DHR instead: the lower it is, the more that option would diversify a DHR holding. Guide: Correlation and diversification →
Show all 1,360 stocks and funds worth at least $500 million that earned more than DHR with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with DHR | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Whole market | +12.8% | 22.9% | 0.64 | −36.4% | +429% | 0.23 | — | |
| 2 | Whole market | +14.7% | 16.8% | 0.91 | −37.0% | +204% | 0.20 | — | |
| 3 | Whole market | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.08 | — | |
| 4 | Whole market | +18.4% | 26.0% | 0.78 | −35.1% | +779% | 0.45 | 0.09% | |
| 5 | Whole market | +17.2% | 24.9% | 0.77 | −30.4% | +285% | 0.25 | — | |
| 6 | Whole market | +11.2% | 20.8% | 0.62 | −37.4% | +319% | -0.01 | — | |
| 7 | Whole market | +15.8% | 24.6% | 0.72 | −30.7% | +576% | 0.27 | — | |
| 8 | Whole market | +8.4% | 15.3% | 0.60 | −28.4% | +202% | 0.61 | 0.08% | |
| 9 | Whole market | +2.5% | 22.1% | 0.23 | −36.9% | +281% | 0.28 | — | |
| 10 | Same or nearby category | +22.8% | 24.9% | 0.95 | −30.5% | +200% | 0.08 | — | |
| 11 | EXPDExpeditors International of Washington, Inc. · Freight & Logistics | Whole market | +12.0% | 27.1% | 0.56 | −35.6% | +349% | 0.55 | — |
| 12 | Same or nearby category | +19.6% | 24.9% | 0.85 | −24.9% | +266% | 0.35 | — | |
| 13 | CIBRFirst Trust Nasdaq Cybersecurity ETF · Cybersecurity | Whole market | +14.1% | 26.1% | 0.64 | −33.9% | +454% | 0.30 | 0.58% |
| 14 | JQUAJPMorgan U.S. Quality Factor ETF · US Quality Equity | Whole market | +13.6% | 15.7% | 0.89 | −32.9% | — | 0.55 | 0.12% |
| 15 | Whole market | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.23 | — | |
| 16 | SJMThe J. M. Smucker Company · Packaged Foods | Whole market | +4.8% | 25.1% | 0.32 | −38.1% | +37.2% | 0.21 | — |
| 17 | FLTWFranklin FTSE Taiwan ETF · Technology | Whole market | +21.8% | 24.3% | 0.94 | −38.0% | — | 0.29 | 0.19% |
| 18 | Whole market | +3.8% | 0.3% | 13.25 | −0.3% | — | 0.07 | 0.09% | |
| 19 | RSPTInvesco S&P 500 Equal Weight Technology ETF · Technology Equity | Whole market | +16.9% | 25.1% | 0.75 | −33.7% | +572% | 0.51 | 0.40% |
| 20 | IWXiShares Russell Top 200 Value ETF · Broad Market | Whole market | +12.7% | 13.8% | 0.94 | −35.8% | +221% | 0.47 | 0.20% |
| 21 | DIVBiShares Core Dividend ETF · Dividend & Income | Whole market | +13.9% | 15.4% | 0.93 | −36.9% | — | 0.49 | 0.05% |
| 22 | DGXQuest Diagnostics Incorporated · Medical Diagnostics | Popular alternative | +12.3% | 22.5% | 0.63 | −36.6% | +243% | 0.26 | — |
| 23 | HACKAmplify Cybersecurity ETF · Technology | Whole market | +12.6% | 25.8% | 0.59 | −38.7% | +373% | 0.31 | 0.60% |
| 24 | FHLCFidelity MSCI Health Care Index ETF · Healthcare | Whole market | +7.3% | 15.4% | 0.53 | −28.8% | +199% | 0.64 | 0.08% |
| 25 | FBTFirst Trust NYSE Arca Biotechnology Index Fund · Healthcare | Whole market | +10.8% | 22.2% | 0.58 | −33.3% | +203% | 0.59 | 0.55% |
| 26 | FXLFirst Trust Technology AlphaDEX Fund · Technology | Whole market | +11.0% | 26.2% | 0.53 | −38.5% | +523% | 0.47 | 0.60% |
| 27 | JAAAJanus Henderson AAA CLO ETF · CLO Bonds | Whole market | +5.1% | 1.7% | 2.98 | −2.6% | — | 0.14 | 0.20% |
| 28 | Whole market | +27.1% | 26.5% | 1.04 | −61.0% | +214% | 0.03 | — | |
| 29 | Whole market | +19.5% | 25.2% | 0.84 | −55.8% | +238% | 0.18 | — | |
| 30 | IHAKiShares Cybersecurity and Tech ETF · Technology | Whole market | +8.3% | 25.0% | 0.44 | −34.4% | — | 0.40 | 0.47% |
| 31 | Whole market | +12.4% | 23.8% | 0.61 | −41.0% | +541% | 0.32 | — | |
| 32 | Whole market | +21.0% | 23.4% | 0.94 | −42.9% | +242% | 0.02 | — | |
| 33 | Whole market | +11.5% | 17.5% | 0.71 | −35.0% | +302% | 0.55 | 0.03% | |
| 34 | Whole market | +16.8% | 26.1% | 0.73 | −42.0% | +374% | 0.20 | — | |
| 35 | RSPHInvesco S&P 500 Equal Weight Health Care ETF · Healthcare | Whole market | +6.1% | 16.8% | 0.44 | −30.4% | +177% | 0.67 | 0.40% |
| 36 | Whole market | +21.0% | 24.8% | 0.90 | −67.2% | +233% | -0.05 | — | |
| 37 | Whole market | +12.8% | 16.9% | 0.80 | −34.0% | +324% | 0.54 | 0.03% | |
| 38 | EBFEnnis, Inc. · Specialty Business Services | Whole market | +11.2% | 21.4% | 0.60 | −35.4% | +163% | 0.22 | — |
| 39 | Whole market | +20.8% | 22.6% | 0.96 | −25.7% | +508% | 0.02 | — | |
| 40 | Whole market | +13.4% | 17.1% | 0.82 | −29.6% | +274% | 0.40 | — | |
| 41 | Whole market | +15.8% | 20.0% | 0.84 | −42.0% | +310% | 0.30 | — | |
| 42 | SVOLSimplify Volatility Premium ETF · Dividend & Income | Whole market | +7.6% | 21.8% | 0.44 | −33.5% | — | 0.47 | 0.66% |
| 43 | Whole market | +18.0% | 25.8% | 0.78 | −59.6% | +234% | 0.02 | — | |
| 44 | Whole market | +17.8% | 21.4% | 0.88 | −53.7% | +140% | -0.06 | — | |
| 45 | Whole market | +22.4% | 22.3% | 1.02 | −46.3% | +347% | 0.08 | — | |
| 46 | Whole market | +23.0% | 25.6% | 0.94 | −61.4% | +278% | 0.03 | — | |
| 47 | Whole market | +22.6% | 24.0% | 0.97 | −57.5% | +373% | 0.31 | — | |
| 48 | LVHIFranklin International Low Volatility High Dividend Index ETF · International Equity | Whole market | +17.0% | 11.1% | 1.48 | −32.4% | +194% | 0.31 | 0.40% |
| 49 | Whole market | +12.9% | 19.9% | 0.71 | −46.9% | +187% | 0.49 | — | |
| 50 | BALTInnovator Defined Wealth Shield ETF · Crypto | Whole market | +6.3% | 3.3% | 1.85 | −4.9% | — | 0.50 | 0.69% |
| 51 | Whole market | +17.4% | 22.9% | 0.82 | −31.4% | +685% | 0.29 | — | |
| 52 | Whole market | +8.2% | 16.4% | 0.57 | −36.0% | +140% | 0.50 | 0.05% | |
| 53 | Whole market | +16.5% | 23.1% | 0.78 | −48.4% | +808% | 0.38 | — | |
| 54 | Whole market | +14.5% | 23.0% | 0.71 | −35.1% | +553% | 0.49 | 0.18% | |
| 55 | VRIGInvesco Variable Rate Investment Grade ETF · Bonds | Whole market | +4.7% | 1.3% | 3.51 | −13.1% | +40.5% | 0.06 | 0.30% |
| 56 | Whole market | +9.0% | 22.9% | 0.49 | −40.8% | +320% | 0.49 | — | |
| 57 | Whole market | +19.7% | 23.2% | 0.90 | −48.8% | +292% | 0.20 | — | |
| 58 | Whole market | +12.1% | 13.7% | 0.90 | −36.8% | +235% | 0.47 | 0.03% | |
| 59 | Whole market | +17.0% | 26.2% | 0.73 | −41.4% | +356% | 0.02 | — | |
| 60 | Whole market | +22.6% | 25.5% | 0.93 | −66.8% | +189% | 0.08 | 0.08% | |
| 61 | Whole market | +12.0% | 25.4% | 0.58 | −55.2% | +240% | 0.23 | — | |
| 62 | Whole market | +9.3% | 16.9% | 0.61 | −35.8% | +153% | 0.50 | 0.03% | |
| 63 | FLRTPacer Aristotle Pacific Floating Rate High Income ETF · Financials | Whole market | +6.0% | 2.3% | 2.55 | −21.0% | +58.0% | 0.20 | 0.60% |
| 64 | CBOECboe Global Markets, Inc. · Capital Markets | Whole market | +21.5% | 25.1% | 0.91 | −43.2% | +463% | 0.12 | — |
| 65 | Whole market | +17.9% | 25.4% | 0.78 | −42.5% | +284% | 0.34 | — | |
| 66 | Same or nearby category | +26.1% | 23.4% | 1.11 | −45.1% | +603% | 0.26 | — | |
| 67 | SDCIUSCF SummerHaven Dynamic Commodity Strategy No K-1 Fund · Bonds | Whole market | +20.6% | 18.4% | 1.12 | −45.7% | — | -0.09 | 0.80% |
| 68 | Whole market | +17.7% | 18.9% | 0.96 | −26.4% | +213% | 0.10 | 0.40% | |
| 69 | Whole market | +5.1% | 18.3% | 0.37 | −23.8% | +145% | 0.08 | — | |
| 70 | Whole market | +11.5% | 20.9% | 0.63 | −32.6% | +394% | 0.31 | — | |
| 71 | KOFCoca-Cola FEMSA, S.A.B. de C.V. · Food & Beverages | Whole market | +22.3% | 24.7% | 0.94 | −55.1% | +119% | 0.35 | — |
| 72 | Whole market | +21.3% | 25.6% | 0.89 | −30.3% | +816% | 0.02 | — | |
| 73 | IHGInterContinental Hotels Group PLC · Hotels & Resorts | Whole market | +21.4% | 26.6% | 0.86 | −59.3% | +383% | 0.32 | — |
| 74 | PAAPlains All American Pipeline, L.P. · Oil & Gas Midstream | Whole market | +27.0% | 25.6% | 1.06 | −87.9% | +64.0% | 0.09 | — |
| 75 | PBAPembina Pipeline Corporation · Oil & Gas Midstream | Whole market | +13.8% | 21.5% | 0.71 | −70.9% | +172% | 0.21 | — |
| 76 | Whole market | +10.4% | 14.1% | 0.78 | −31.7% | +258% | 0.53 | 0.04% | |
| 77 | Whole market | +6.1% | 27.5% | 0.35 | −42.0% | +63.3% | 0.25 | — | |
| 78 | Whole market | +5.0% | 27.0% | 0.32 | −36.8% | +129% | 0.31 | — | |
| 79 | Whole market | 0.0% | 24.7% | 0.12 | −38.0% | +217% | 0.47 | — | |
| 80 | Whole market | +24.2% | 22.8% | 1.07 | −32.4% | +406% | 0.26 | — | |
| 81 | Whole market | +9.7% | 14.3% | 0.72 | −33.4% | +252% | 0.44 | 0.06% | |
| 82 | Whole market | +2.7% | 2.9% | 0.94 | −6.3% | +32.7% | 0.30 | 0.03% | |
| 83 | Whole market | +7.1% | 22.9% | 0.42 | −38.7% | +295% | 0.40 | — | |
| 84 | RGAReinsurance Group of America, Incorporated · Insurance | Whole market | +19.7% | 27.3% | 0.80 | −65.8% | +199% | 0.14 | — |
| 85 | Same or nearby category | +16.3% | 24.8% | 0.74 | −43.4% | +241% | 0.18 | — | |
| 86 | DRIDarden Restaurants, Inc. · Restaurants | Whole market | +12.4% | 27.2% | 0.57 | −72.8% | +361% | 0.14 | — |
| 87 | Whole market | +11.1% | 24.2% | 0.56 | −36.7% | +204% | -0.03 | — | |
| 88 | Whole market | +10.3% | 16.2% | 0.69 | −34.2% | +223% | 0.55 | 0.06% | |
| 89 | FLOTiShares Floating Rate Bond ETF · Floating Rate Bonds | Whole market | +4.5% | 1.8% | 2.48 | −13.5% | +35.9% | 0.10 | 0.15% |
| 90 | Whole market | +11.3% | 18.8% | 0.67 | −38.4% | +170% | 0.20 | — | |
| 91 | Whole market | +6.8% | 19.4% | 0.44 | −38.7% | +122% | 0.37 | 0.09% | |
| 92 | Whole market | +5.2% | 17.5% | 0.38 | −36.4% | +102% | 0.38 | 0.06% | |
| 93 | Whole market | +5.2% | 8.9% | 0.61 | −25.4% | +37.8% | 0.12 | — | |
| 94 | Whole market | +13.9% | 18.5% | 0.80 | −34.0% | +446% | 0.19 | — | |
| 95 | Whole market | +2.9% | 17.9% | 0.25 | −36.9% | +181% | 0.22 | — | |
| 96 | EWTiShares MSCI Taiwan ETF · International Equity | Whole market | +20.4% | 24.2% | 0.89 | −38.9% | +468% | 0.30 | 0.59% |
| 97 | Whole market | +5.5% | 21.5% | 0.36 | −30.1% | +89.8% | 0.39 | — | |
| 98 | PJULInnovator U.S. Equity Power Buffer ETF · Broad Market | Whole market | +10.5% | 8.6% | 1.20 | −18.2% | — | 0.54 | 0.79% |
| 99 | Whole market | +14.8% | 23.6% | 0.71 | −32.8% | +625% | 0.43 | — | |
| 100 | Whole market | +9.3% | 19.2% | 0.56 | −30.1% | +344% | 0.10 | — |
DHR against its popular alternatives
The investments people most often weigh against DHR, compared period by period and year by year.
How do DHR's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at DHR, which divides the map into what did better or worse on each measure.
- Five of the 19 popular alternatives, led by DGX, LH and TMO, were both more rewarding and calmer than DHR over the past 5 years, earning a higher annual return with lower volatility.
- Over the past 5 years, DHR returned -3.8% a year, less than the S&P 500's 12.7%, with higher volatility (29.1% against 17.1%).
Green points earned more than DHR with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| DGX Quest Diagnostics Incorporated | +12.3% | 22.5% |
| LH Labcorp Holdings Inc. | +7.3% | 23.8% |
| WAT Waters Corporation | +4.5% | 33.9% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| A Agilent Technologies, Inc. | +2.6% | 30.6% |
| MTD Mettler-Toledo International Inc. | +2.6% | 32.5% |
| IQV IQVIA Holdings Inc. | +1.3% | 34.7% |
| QGEN Qiagen N.V. | +0.6% | 26.9% |
| ABT Abbott Laboratories | −1.7% | 23.1% |
| RVTY Revvity, Inc. | −2.2% | 35.1% |
| DHR This pageDanaher Corporation | −3.8% | 29.1% |
| BRKR Bruker Corporation | −6.3% | 44.3% |
| RGEN Repligen Corporation | −7.8% | 51.3% |
| ILMN Illumina, Inc. | −7.8% | 46.9% |
| TECH Bio-Techne Corporation | −10.2% | 39.4% |
| BIO Bio-Rad Laboratories, Inc. | −13.9% | 37.9% |
| TXG 10x Genomics, Inc. | −15.1% | 70.8% |
| AVTR Avantor, Inc. | −15.5% | 41.0% |
| SDGR Schrödinger, Inc. | −16.0% | 65.7% |
| PACB Pacific Biosciences of California, Inc. | −40.0% | 97.0% |
Has DHR consistently beaten its popular alternatives?
This section compares DHR with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than DHR helps separate lasting outperformance from a single strong stretch.
- Ten of the 19 popular alternatives, led by A, MTD and TMO, outperformed DHR in at least 3 of 5 short-term and 2 of 3 long-term timeframes.
- A, MTD and TMO outperformed DHR in every long-term period and in all but one short-term period, the most consistent record in the group.
- DGX, MTD and TMO earned more for the risk they took than DHR (a higher Sharpe ratio) and fell less in their worst decline of the past 10 years.
A green cell means the alternative earned more than DHR over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| DHR Danaher Corporation (this page) | — | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| A QualifiedAgilent Technologies, Inc. | 5/5 short3/3 longAll-weather | +7.1% | +33.1% | +43.6% | +26.4% | +22.0% | +62.1% | +13.8% | +306% | 30.6% | 0.24 | −43.2% | — | $49B | — |
| MTD QualifiedMettler-Toledo International Inc. | 5/5 short3/3 longAll-weather | +14.2% | +28.3% | +23.4% | +15.8% | +20.4% | +60.2% | +13.7% | +298% | 32.5% | 0.24 | −43.5% | — | $33B | — |
| TMO QualifiedThermo Fisher Scientific Inc. | 4/5 short3/3 longAll-weather | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| IQV QualifiedIQVIA Holdings Inc. | 4/5 short3/3 longAll-weather | −0.8% | +31.4% | +51.5% | +18.8% | +26.3% | +45.3% | +6.5% | +260% | 34.7% | 0.21 | −51.5% | — | $44B | — |
| DGX QualifiedQuest Diagnostics Incorporated | 4/5 short3/3 longAll-weather | −2.9% | +14.5% | +21.6% | +38.6% | +26.5% | +103% | +78.5% | +243% | 22.5% | 0.63 | −36.6% | — | $26B | — |
| RVTY QualifiedRevvity, Inc. | 5/5 short2/3 long | +8.6% | +46.6% | +67.8% | +59.3% | +64.0% | +54.6% | −10.6% | +203% | 35.1% | 0.11 | −59.0% | — | $17B | — |
| RGEN QualifiedRepligen Corporation | 4/5 short2/3 long | −1.0% | +22.9% | +35.5% | +8.8% | +15.8% | +22.5% | −33.3% | +514% | 51.3% | 0.10 | −68.3% | — | $11B | — |
| LH QualifiedLabcorp Holdings Inc. | 4/5 short2/3 long | +0.7% | +15.0% | +20.6% | +29.3% | +12.2% | +67.4% | +42.4% | +184% | 23.8% | 0.42 | −46.6% | — | $26B | — |
| WAT QualifiedWaters Corporation | 4/5 short2/3 long | +4.5% | +23.9% | +31.9% | +15.9% | +29.0% | +74.6% | +24.4% | +182% | 33.9% | 0.30 | −44.3% | — | $43B | — |
| QGEN QualifiedQiagen N.V. | 4/5 short2/3 long | +9.2% | +20.8% | +20.2% | +8.7% | +6.3% | +45.9% | +3.0% | +111% | 26.9% | 0.15 | −41.4% | — | $10B | — |
| ABT Medical - DevicesAbbott Laboratories | 0/5 short2/3 long | +0.3% | +1.6% | +8.4% | −15.3% | −18.7% | +13.0% | −8.0% | +204% | 23.1% | 0.04 | −39.6% | — | $178B | — |
| ILMN Medical - Diagnostics & ResearchIllumina, Inc. | 5/5 short1/3 long | +12.2% | +45.1% | +102% | +99.4% | +169% | +130% | −33.3% | +93.0% | 46.9% | 0.06 | −86.2% | — | $40B | — |
| BIO Medical - DevicesBio-Rad Laboratories, Inc. | 4/5 short1/3 long | −6.0% | +17.4% | +16.9% | +16.1% | +10.1% | +14.1% | −52.5% | +115% | 37.9% | -0.21 | −73.8% | — | $9.5B | — |
| TXG Biotechnology10x Genomics, Inc. | 4/5 short1/3 long | −9.7% | +65.3% | +191% | +330% | +444% | +81.2% | −55.8% | — | 70.8% | 0.12 | −96.5% | — | $9.3B | — |
| TECH BiotechnologyBio-Techne Corporation | 3/5 short1/3 long | +0.2% | +1.4% | +20.2% | +22.2% | +16.7% | +15.1% | −41.4% | +191% | 39.4% | -0.08 | −67.2% | — | $11B | — |
| AVTR Medical - Instruments & SuppliesAvantor, Inc. | 5/5 short0/3 long | +10.1% | +55.9% | +95.5% | +45.0% | +9.5% | −19.1% | −56.9% | — | 41.0% | -0.20 | −83.2% | — | $11B | — |
| BRKR Medical - DevicesBruker Corporation | 3/5 short0/3 long | −9.2% | −0.3% | +36.3% | +16.6% | +47.4% | −5.0% | −27.7% | +171% | 44.3% | 0.08 | −68.7% | — | $8.5B | — |
| PACB Medical - DevicesPacific Biosciences of California, Inc. | 3/5 short0/3 long | +44.1% | +44.1% | +12.6% | +6.5% | −1.0% | −73.5% | −92.2% | −77.9% | 97.0% | -0.04 | −98.2% | — | $609M | — |
| SDGR Software - ApplicationSchrödinger, Inc. | 3/5 short0/3 long | −22.6% | +56.0% | +82.8% | +30.1% | +6.5% | +6.5% | −58.2% | — | 65.7% | 0.06 | −90.2% | — | $1.8B | — |
How did DHR do year by year?
This table shows each investment's total return in every full calendar year since 1997, along with where DHR ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with DHR and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
- DHR finished ahead of the S&P 500 in 19 of its 29 full calendar years, and behind it in each of the last four.
- Ranked against its popular alternatives each year, DHR finished in the top quarter in six of 29 years and in the bottom quarter in two. In 2025, it ranked 13 of 20.
- Among its popular alternatives, IQV came out ahead of DHR most often, in seven of the 12 years both traded.
Newest year first. Green marks a year in which the fund came out ahead of DHR; gray means the two finished within a fraction of a point. The rank row places DHR among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of DHR | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR This pageDanaher Corporation | — | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% | +9.3% | +11.6% | +38.3% | +19.1% | −0.1% | +25.7% | +33.0% | −35.4% | +21.3% | +30.1% | −2.7% | +25.3% | +39.7% | +9.1% | −11.7% | +41.5% | −11.0% | +72.4% | +35.2% |
| Rank among alternatives | Top quarter in 6 of 29 | 13 of 20 | 9 of 20 | 10 of 20 | 8 of 20 | 8 of 20 | 9 of 19 | 5 of 17 | 8 of 17 | 13 of 17 | 1 of 17 | 12 of 17 | 11 of 17 | 7 of 16 | 9 of 16 | 4 of 16 | 6 of 15 | 7 of 15 | 8 of 15 | 9 of 15 | 6 of 15 | 13 of 15 | 6 of 15 | 9 of 15 | 3 of 15 | 8 of 15 | 8 of 13 | 10 of 12 | 2 of 12 | 2 of 11 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 9 of 29 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% | +1.2% | +13.5% | +32.3% | +16.0% | +1.9% | +15.1% | +26.4% | −36.8% | +5.1% | +15.9% | +4.8% | +10.7% | +28.2% | −21.6% | −11.7% | −9.8% | +20.4% | +28.7% | +33.5% |
| A Agilent Technologies, Inc. | 8 of 26 | +1.9% | −2.7% | −6.4% | −5.5% | +35.5% | +39.8% | +27.5% | +1.7% | +48.3% | +10.2% | +3.5% | +0.8% | +41.1% | +18.4% | −15.7% | +33.4% | +98.7% | −57.4% | +5.4% | +11.1% | +38.1% | −17.6% | +62.8% | −37.0% | −47.9% | −29.2% | — | — | — |
| MTD Mettler-Toledo International Inc. | 14 of 28 | +13.9% | +0.9% | −16.1% | −14.8% | +48.9% | +43.7% | +40.3% | −8.7% | +48.0% | +23.4% | +12.1% | +24.7% | +25.5% | +30.9% | −2.3% | +44.0% | +55.8% | −40.8% | +44.3% | +42.8% | +7.6% | +21.6% | +31.7% | −38.2% | −4.7% | +42.4% | +36.1% | +62.7% | — |
| TMO Thermo Fisher Scientific Inc. | 14 of 29 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% | +13.8% | +13.1% | +75.8% | +43.2% | −18.8% | +16.1% | +40.0% | −40.9% | +27.4% | +50.3% | −0.2% | +19.8% | +25.3% | −15.7% | +5.6% | +98.2% | −11.4% | −61.5% | +6.7% |
| IQV IQVIA Holdings Inc. | 7 of 12 | +14.7% | −15.1% | +12.9% | −27.4% | +57.5% | +16.0% | +33.0% | +18.7% | +28.7% | +10.8% | +16.6% | +27.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| DGX Quest Diagnostics Incorporated | 11 of 29 | +17.2% | +11.8% | −10.1% | −7.4% | +47.9% | +14.1% | +31.1% | −13.8% | +9.1% | +31.9% | +8.4% | +28.0% | −6.2% | +1.5% | +8.4% | −10.0% | +17.2% | −1.1% | +0.6% | +3.7% | +8.5% | +31.6% | +28.5% | −20.7% | +1.0% | +364% | +72.0% | +5.4% | +11.3% |
| RVTY Revvity, Inc. | 12 of 29 | −13.1% | +2.4% | −21.9% | −30.1% | +40.4% | +48.2% | +24.0% | +7.8% | +40.8% | −2.1% | +23.2% | +6.8% | +31.0% | +60.4% | −21.6% | +27.1% | +50.6% | −45.9% | +18.4% | −4.5% | +6.2% | +33.9% | +112% | −75.7% | −32.7% | +154% | +52.5% | +36.6% | +6.4% |
| RGEN Repligen Corporation | 14 of 29 | +13.8% | −20.0% | +6.2% | −36.1% | +38.2% | +107% | +75.4% | +45.4% | +17.7% | +8.9% | +42.9% | +45.2% | +117% | +81.0% | −26.0% | +14.1% | +8.7% | −42.3% | +133% | −29.8% | +38.9% | −34.1% | +43.8% | +25.1% | −28.1% | +8.0% | +145% | +63.8% | −34.4% |
| LH Labcorp Holdings Inc. | 15 of 29 | +10.6% | +2.2% | +13.8% | −24.4% | +54.4% | +20.3% | +33.9% | −20.8% | +24.3% | +3.8% | +14.6% | +18.1% | +5.5% | +0.8% | −2.2% | +17.5% | +16.2% | −14.7% | +2.8% | +36.5% | +8.1% | +34.8% | +59.0% | −42.5% | −8.1% | +377% | +168% | −21.6% | −39.0% |
| WAT Waters Corporation | 14 of 29 | +2.4% | +12.7% | −3.9% | −8.1% | +50.6% | +5.9% | +23.9% | −2.4% | +43.8% | −0.1% | +19.4% | +12.7% | +14.8% | +17.6% | −4.7% | +25.4% | +69.1% | −53.6% | +61.5% | +29.5% | −19.2% | +41.1% | +52.3% | −43.8% | −53.6% | +215% | +21.5% | +129% | +25.6% |
| QGEN Qiagen N.V. | 13 of 29 | +12.5% | +2.6% | −12.9% | −10.3% | +5.2% | +56.4% | −1.9% | +11.4% | +10.7% | +1.3% | +17.8% | −1.5% | +31.2% | +31.4% | −29.3% | −12.4% | +27.1% | −16.5% | +39.1% | +28.8% | +7.3% | −8.5% | +131% | −72.1% | −46.3% | +83.3% | +150% | +35.3% | +73.4% |
| ABT Abbott Laboratories | 10 of 29 | +12.9% | +4.8% | +2.3% | −20.7% | +30.5% | +28.1% | +22.1% | +29.1% | +52.0% | −12.3% | +1.9% | +20.1% | +24.3% | +20.3% | +21.8% | −8.3% | +4.6% | −2.5% | +18.1% | +26.9% | −13.5% | +9.2% | +19.3% | −26.8% | +17.0% | +35.8% | −24.7% | +51.9% | +31.4% |
| ILMN Illumina, Inc. | 12 of 25 | −1.8% | −1.3% | −31.1% | −46.9% | +2.8% | +11.5% | +10.6% | +37.3% | +70.7% | −33.3% | +4.0% | +66.9% | +99.0% | +82.4% | −51.9% | +106% | +17.8% | −12.1% | +50.8% | +179% | +48.6% | +34.4% | +109% | −71.3% | −26.9% | — | — | — | — |
| BIO Bio-Rad Laboratories, Inc. | 12 of 29 | −7.8% | +1.7% | −23.2% | −44.4% | +29.6% | +57.5% | +59.4% | −2.7% | +30.9% | +31.5% | +15.0% | −2.5% | +17.7% | +9.4% | −7.5% | +7.7% | +28.1% | −27.3% | +25.6% | +26.1% | +14.1% | −0.5% | +49.0% | +22.3% | +99.1% | +36.0% | +11.3% | −19.6% | −12.9% |
| TXG 10x Genomics, Inc. | 3 of 6 | +13.6% | −74.3% | +53.6% | −75.5% | +5.2% | +85.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| TECH Bio-Techne Corporation | 10 of 29 | −17.9% | −6.3% | −6.5% | −35.7% | +63.4% | +45.4% | +52.7% | +12.6% | +27.5% | +15.8% | −1.3% | −1.1% | +40.9% | +1.9% | +5.5% | −2.5% | +8.0% | −1.9% | +19.2% | −1.2% | +44.3% | +2.8% | +32.5% | −22.4% | +2.0% | +31.1% | +160% | +20.9% | +33.8% |
| AVTR Avantor, Inc. | 2 of 6 | −45.6% | −7.7% | +8.3% | −50.0% | +49.7% | +55.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| BRKR Bruker Corporation | 12 of 25 | −19.3% | −20.0% | +7.8% | −18.3% | +55.3% | +6.6% | +71.8% | −12.8% | +62.7% | −12.2% | +23.7% | −0.8% | +29.8% | +22.7% | −25.2% | +37.7% | +199% | −69.7% | +77.1% | +54.5% | +20.7% | −11.5% | −6.4% | −70.3% | −30.6% | — | — | — | — |
| PACB Pacific Biosciences of California, Inc. | 7 of 15 | +2.2% | −81.3% | +19.9% | −60.0% | −21.1% | +405% | −30.5% | +180% | −30.5% | −71.1% | +67.5% | +49.9% | +208% | −39.3% | −82.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SDGR Schrödinger, Inc. | 1 of 5 | −7.3% | −46.1% | +91.5% | −46.3% | −56.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Risk and diversification
How DHR has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were DHR's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents DHR's five deepest drawdowns since it began trading in 1986, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
- Not every decline was the market's doing: DHR fell 45.9% from April 1999 to March 2000, while the S&P 500 rose 0.6%.
- In two of DHR's three worst declines, the S&P 500 held up better over the same dates.
- The longest climb back to a previous high took 20 months, after DHR fell 45.7% from December 2007 to March 2009.
Green means DHR fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | DHR fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| No named crash | −60.9% | — | Sep 1987 | Dec 1987 | 3 months | Jun 1988 | 6 months |
| No named crash | −45.9% | +0.6% | Apr 1999 | Mar 2000 | 11 months | Dec 2000 | 9 months |
| 2008 financial crisis | −45.7% | −53.3% | Dec 2007 | Mar 2009 | 15 months | Nov 2010 | 20 months |
| 2022 bear market | −43.8% | +74.1% | Sep 2021 | May 2026 | 4.7 years | Not yet | — |
| No named crash | −38.6% | — | Jul 1990 | Nov 1990 | 4 months | Jun 1991 | 7 months |
How did DHR do in stock market crashes?
This section measures how far DHR, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
- None of its popular alternatives fell less than DHR in most of the crashes they both traded through.
- DHR fell less than the S&P 500 in six of the ten crashes it has traded through. The clearest case was the dot-com bust, when DHR fell 33.7% and the S&P 500 fell 47.5%.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than DHR.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR This pageDanaher Corporation | — | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| SPY S&P 500State Street SPDR S&P 500 ETF | 3 of 10 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| A Agilent Technologies, Inc. | 1 of 10 | −3.7% | −25.3% | −25.8% | −16.1% | −8.7% | −17.6% | −37.3% | −4.2% | −67.6% | −92.4% |
| MTD Mettler-Toledo International Inc. | 1 of 10 | −3.8% | −33.9% | −23.8% | −17.7% | −10.0% | −16.9% | −21.5% | −4.3% | −60.6% | −53.7% |
| TMO Thermo Fisher Scientific Inc. | 4 of 10 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| IQV IQVIA Holdings Inc. | 1 of 6 | −6.8% | −35.9% | −48.9% | −19.2% | −5.3% | −28.7% | — | — | — | — |
| DGX Quest Diagnostics Incorporated | 5 of 10 | −2.7% | −22.3% | −35.0% | −26.1% | −6.5% | −17.8% | −19.3% | −1.0% | −29.2% | −46.6% |
| RVTY Revvity, Inc. | 1 of 10 | −3.2% | −38.1% | −29.3% | −26.1% | −7.7% | −23.6% | −31.2% | −3.4% | −62.6% | −91.6% |
| RGEN Repligen Corporation | 3 of 10 | −4.9% | −38.7% | −22.2% | −29.9% | −8.6% | −44.4% | −17.1% | −3.7% | −51.9% | −90.7% |
| LH Labcorp Holdings Inc. | 3 of 10 | −4.7% | −29.6% | −45.5% | −30.6% | −3.8% | −19.5% | −18.4% | −1.4% | −33.5% | −63.1% |
| WAT Waters Corporation | 2 of 10 | −1.6% | −26.3% | −25.3% | −14.7% | −9.7% | −16.6% | −26.4% | −3.4% | −60.7% | −80.1% |
| QGEN Qiagen N.V. | 5 of 10 | −0.4% | −21.3% | −12.4% | −14.0% | −7.0% | −27.8% | −25.9% | −2.6% | −45.1% | −92.1% |
| ABT Abbott Laboratories | 5 of 10 | −2.5% | −27.9% | −29.7% | −11.7% | −8.8% | −27.4% | −11.5% | −0.5% | −22.3% | −45.7% |
| ILMN Illumina, Inc. | 1 of 9 | −6.7% | −58.2% | −31.0% | −25.8% | −5.3% | −36.1% | −48.7% | −1.9% | −57.9% | — |
| BIO Bio-Rad Laboratories, Inc. | 4 of 10 | −1.9% | −45.3% | −21.8% | −29.7% | −8.0% | −18.1% | −25.4% | −0.5% | −50.9% | −29.1% |
| TXG 10x Genomics, Inc. | 0 of 3 | −8.1% | −81.1% | −43.1% | — | — | — | — | — | — | — |
| TECH Bio-Techne Corporation | 4 of 10 | −3.6% | −39.6% | −23.5% | −34.8% | −4.5% | −24.9% | −18.8% | −0.4% | −43.8% | −69.6% |
| AVTR Avantor, Inc. | 0 of 3 | −6.2% | −50.5% | −53.9% | — | — | — | — | — | — | — |
| BRKR Bruker Corporation | 1 of 9 | −2.5% | −38.0% | −36.2% | −24.1% | −13.4% | −19.9% | −39.0% | −5.5% | −80.2% | — |
| PACB Pacific Biosciences of California, Inc. | 0 of 7 | −6.7% | −79.3% | −47.4% | −28.1% | −10.0% | −34.7% | −75.2% | — | — | — |
| SDGR Schrödinger, Inc. | 0 of 3 | −7.6% | −40.8% | −45.4% | — | — | — | — | — | — | — |
How closely does DHR move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares DHR with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- Only DGX and RGEN had a higher capture ratio (upside capture divided by downside capture) than DHR's 1.01, out of 16 popular alternatives with the same record.
- DGX took just 54% of the S&P 500's losses, against 84% for DHR, while still keeping 69% of its gains.
- Over the past 10 years, DHR captured 84% of the S&P 500's gains in rising months and 84% of its losses in falling months, with a beta of 0.75. That is a defensive profile: it gave up some of the market's upside in exchange for smaller losses.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than DHR's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| DHR This pageDanaher Corporation | 84% | 84% | 1.01 | 0.75 |
| DGX Quest Diagnostics Incorporated | 69% | 54% | 1.28 | 0.80 |
| RGEN Repligen Corporation | 119% | 108% | 1.11 | 0.99 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| ABT Abbott Laboratories | 76% | 79% | 0.96 | 0.64 |
| LH Labcorp Holdings Inc. | 81% | 91% | 0.89 | 0.97 |
| A Agilent Technologies, Inc. | 120% | 141% | 0.85 | 1.13 |
| MTD Mettler-Toledo International Inc. | 118% | 143% | 0.83 | 1.13 |
| IQV IQVIA Holdings Inc. | 128% | 167% | 0.77 | 1.31 |
| WAT Waters Corporation | 107% | 139% | 0.77 | 1.01 |
| RVTY Revvity, Inc. | 111% | 146% | 0.76 | 1.10 |
| QGEN Qiagen N.V. | 62% | 83% | 0.75 | 0.45 |
| BRKR Bruker Corporation | 121% | 160% | 0.75 | 1.27 |
| TECH Bio-Techne Corporation | 120% | 162% | 0.74 | 1.23 |
| BIO Bio-Rad Laboratories, Inc. | 104% | 146% | 0.71 | 0.99 |
| ILMN Illumina, Inc. | 120% | 200% | 0.60 | 1.19 |
| PACB Pacific Biosciences of California, Inc. | 76% | 234% | 0.33 | 1.70 |
What diversifies DHR?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with DHR's. Because such investments tend not to fall at the same time, pairing DHR with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in DHR into LVHI would have cut the portfolio's volatility by 17% over the past 5 years and raised its annual return (-3.4% for DHR alone, +0.8% for the mix).
- MCK made money in six of the eight calendar years in which DHR lost money.
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of DHR over the past 5 years, with correlations of 0.31 or lower, and each still earned a positive 5-year return.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which DHR lost money. The last two columns show a portfolio that is 80% DHR and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2023 | 2022 | 2011 | 2008 | 2005 | 2001 | 1999 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR Danaher Corporation (this page) | 1.00 | −17.6% | 0.01 | −0.4% | −1.2% | −19.0% | −0.1% | −35.4% | −2.7% | −11.7% | −11.0% | 22.3% | −3.4% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.31 | +119% | 1.48 | +15.9% | +17.4% | +3.8% | — | — | — | — | — | 18.5% | +0.8% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.30 | +225% | 1.34 | +29.8% | +42.0% | +6.0% | −16.1% | −20.8% | — | — | — | 18.7% | +2.5% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.26 | +101% | 1.04 | +33.4% | +8.0% | +10.4% | — | — | — | — | — | 18.8% | +0.6% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.34 | +83.3% | 1.00 | +14.1% | +1.8% | +7.1% | — | — | — | — | — | 19.0% | −0.1% |
| FTLS Broad MarketFirst Trust Long/Short Equity ETF | 0.46 | +62.9% | 0.99 | +18.8% | +16.9% | −5.6% | — | — | — | — | — | 18.7% | −0.4% |
| SMH TechnologyVanEck Semiconductor ETF | 0.43 | +323% | 0.97 | +39.1% | +73.4% | −33.5% | +6.8% | −44.7% | +10.8% | −14.6% | — | 21.7% | +4.6% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.46 | +85.0% | 0.96 | +13.4% | +20.1% | −5.1% | — | — | — | — | — | 18.9% | +0.2% |
| GLD CommoditiesSPDR Gold Shares | 0.10 | +126% | 0.96 | +26.7% | +12.7% | −0.8% | +9.6% | +4.9% | +17.8% | — | — | 18.5% | +1.2% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2024 | 2023 | 2022 | 2011 | 2008 | 2005 | 2001 | 1999 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR Danaher Corporation (this page) | 1.00 | −17.6% | 0.01 | −0.4% | −1.2% | −19.0% | −0.1% | −35.4% | −2.7% | −11.7% | −11.0% | 22.3% | −3.4% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.23 | +479% | 1.55 | +19.0% | +34.1% | +54.1% | +8.1% | −39.6% | +18.7% | −2.5% | −36.8% | 19.7% | +4.6% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.10 | +3,143% | 1.47 | +215% | +160% | +1.3% | −24.4% | −20.5% | −25.2% | −25.6% | +350% | 22.3% | +16.2% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.20 | +1,636% | 1.46 | +107% | +79.6% | +17.0% | −17.0% | −15.2% | +20.1% | +73.7% | −58.7% | 21.5% | +12.4% |
| MCK Medical - DistributionMcKesson Corporation | 0.08 | +413% | 1.44 | +23.7% | +24.1% | +51.8% | +11.8% | −40.4% | +64.9% | +4.9% | −71.3% | 18.9% | +4.1% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.13 | +690% | 1.41 | −4.0% | +30.4% | +86.6% | — | — | — | — | — | 19.7% | +6.5% |
Common questions
What was DHR's worst drawdown?
DHR's deepest decline since it began trading in 1986 was 60.9%, from September to December 1987. It took six months from the low to climb back to its old high.
What were DHR's best and worst years?
Over 29 full calendar years, DHR's best year was 2016, when it returned 73.2%. Its worst was 2008, with a return of -35.4%.
Is there a better investment than DHR?
Among DHR's popular alternatives, DGX, LH and QGEN earned more than DHR with less volatility over the past 5 years. DGX returned 12.3% a year at 22.5% volatility, against a loss of 3.8% a year at 29.1%. Looking beyond its popular alternatives, GILD (biotechnology) and AMGN (biotechnology) earned more than DHR with less volatility over the past 5 years. GILD returned 22.8% a year at 24.9% volatility, against a loss of 3.8% a year at 29.1%.
Is DHR more volatile than the S&P 500?
Yes. DHR's volatility over the past 5 years was 29.1%, 1.7 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, DHR's return lands within 29.1% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is DHR's Sharpe ratio?
DHR's Sharpe ratio over the past 5 years was 0.01, against 0.79 for the S&P 500, so DHR earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is DHR with the S&P 500?
Over the past 5 years, DHR's monthly returns had a correlation of 0.54 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against DHR instead: the lower it is, the more that option would diversify a DHR holding.
What are the best alternatives to DHR?
Of the 19 popular alternatives we compared, ten outperformed DHR in at least 3 of 5 short-term and 2 of 3 long-term timeframes, with dividends reinvested: A, MTD and TMO.
Did DHR outperform the S&P 500?
DHR finished ahead of the S&P 500 (SPY) in 19 of 29 full calendar years. In 2025, it returned +0.4%, against +17.7% for the index.
How did DHR do in stock market crashes?
DHR fell less than the S&P 500 (SPY) in six of the ten major crashes it has traded through, and further in three. The clearest case was the dot-com bust, when DHR fell 33.7% and the S&P 500 fell 47.5%.
What diversifies DHR?
These had a low correlation with DHR over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.31), DXJ (correlation 0.30) and EMLP (correlation 0.26); among large stocks, CAH (correlation 0.23), CLS (correlation 0.10) and FIX (correlation 0.20). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than DHR's. Returns within 0.5 points or 3% of DHR's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.